Want to see RARE full AI Analyst Report?
RARE Stock Chart & Stats
$24.81
-$0.60(-1.35%)
At close: 4:00 PM EST
$24.81
-$0.60(-1.35%)
Day’s Range― - ―
52-Week Range$18.29 - $39.89
Previous CloseN/A
Volume75.38K
Average Volume (3M)2.63M
Market Cap
$2.88B
Enterprise Value$2.89K
Total Cash (Recent Filing)$413.00M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Jul 30, 2026EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.11
Shares Outstanding98,489,230
10 Day Avg. Volume1,908,618
30 Day Avg. Volume2,628,119
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)-28.35
Price to Sales (P/S)3.37
P/FCF Ratio-4.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$54.00Price Target Upside117.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.36
Revenue Forecast (FY)$741.43M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~84% gross margins reflect strong pricing power and low incremental cost of goods for orphan therapies. This durable unit economics means each additional patient contributes high gross profit, supporting eventual operating leverage as SG&A and R&D are reduced.
Commercial Scale & Patient ReachA diversified global commercial footprint and established patient bases reduce single-market concentration and support predictable recurring product sales. Durable specialty distribution, payer relationships and multi-country reimbursement improve long-term revenue resilience.
Near-term Regulatory CatalystsClear, near-term regulatory milestones create structural value optionality: approvals would materially expand addressable markets and shift the revenue mix toward durable, high-margin gene therapies. Successful filings also validate R&D strategy and de-risk future programs.
Bears Say
High Cash BurnPersistent ~-$497M TTM operating cash use signals structural negative cash generation that requires ongoing external funding or asset monetization. This constrains strategic flexibility, can dilute shareholders, and makes execution dependent on near-term financing or non‑operational receipts.
Stressed Balance Sheet & LeverageNegative equity and ~$1.2B debt materially weaken the balance sheet, limiting borrowing capacity and increasing vulnerability to adverse market conditions. Elevated leverage reduces headroom for strategic investments and raises refinancing and covenant risks over the medium term.
Dependence On PRVs & Launch ExecutionManagement's path to profitability relies on monetizing Priority Review Vouchers and flawless commercial launches. These are binary or timing-sensitive events; delays, lower-than-modeled PRV proceeds, or launch setbacks would prolong cash needs and undermine the planned path to sustainable profitability.
Ultragenyx Pharmaceutical News
RARE FAQ
What was Ultragenyx Pharmaceutical, Inc.’s price range in the past 12 months?
Ultragenyx Pharmaceutical, Inc. lowest stock price was $18.29 and its highest was $39.89 in the past 12 months.
What is Ultragenyx Pharmaceutical, Inc.’s market cap?
Ultragenyx Pharmaceutical, Inc.’s market cap is $2.88B.
When is Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date?
Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Ultragenyx Pharmaceutical, Inc.’s earnings last quarter?
Ultragenyx Pharmaceutical, Inc. released its earnings results on May 05, 2026. The company reported -$1.84 earnings per share for the quarter, missing the consensus estimate of -$1.488 by -$0.352.
Is Ultragenyx Pharmaceutical, Inc. overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical, Inc.’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical, Inc. pay dividends?
Ultragenyx Pharmaceutical, Inc. does not currently pay dividends.
What is Ultragenyx Pharmaceutical, Inc.’s EPS estimate?
Ultragenyx Pharmaceutical, Inc.’s EPS estimate is -1.23.
How many shares outstanding does Ultragenyx Pharmaceutical, Inc. have?
Ultragenyx Pharmaceutical, Inc. has 98,489,230 shares outstanding.
What happened to Ultragenyx Pharmaceutical, Inc.’s price movement after its last earnings report?
Ultragenyx Pharmaceutical, Inc. reported an EPS of -$1.84 in its last earnings report, missing expectations of -$1.488. Following the earnings report the stock price went up 3.679%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical, Inc.?
Currently, no hedge funds are holding shares in RARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ultragenyx Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (117.65% Upside)
$54.00 (117.65% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $623.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.82%
12-Months-Change
Fundamentals
Return on Equity
1566.94%
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
RARE Stock 12 Month Forecast
Average Price Target
$54.00
▲(117.65% Upside)
Technical Analysis
Travere Therapeutics
―
Xenon
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
3.96% Insiders
19.37% Mutual Funds
0.23% Other Institutional Investors
56.66% Public Companies and
Individual Investors